Regulatory chaperone complexes in neurodegenerative diseases: A perspective on therapeutic intervention

Current Alzheimer Research

Volumn 11, Issue 1, 2014, Pages 59-68

  Carman, Aaron ^a   Kishinevsky, Sarah ^a   Koren III, John ^a   Luo, Wenjie ^b   Chiosis, Gabriela ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Aberrant neurological proteins; Chaperone inhibitors; Molecular chaperones; Neurodegeneration

Indexed keywords

ALPHA SYNUCLEIN; CHAPERONE; COPPER ZINC SUPEROXIDE DISMUTASE; FUSED IN SARCOMA PROTEIN; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; LEUCINE RICH REPEAT KINASE 2; POLYGLUTAMINE; TAR DNA BINDING PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; NERVE DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TAUOPATHY;

EID: 84891799357     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205010666131119233044     Document Type: Article

References (145)

1. Hartl FU, Hayer-Hartl M. Converging concepts of protein folding in vitro and in vivo. Nat Struct Mol Biol 16(6): 574-581.
2. Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes Da- Gama EM, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by hsp90. Nat Chem Biol 7(11): 818-826 (2011).
3. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of hsp90 confers tumour selectivity on hsp90 inhibitors. Nature 425(6956): 407-410 (2003).
4. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, et al. The high-affinity hsp90-chip complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117(3): 648-658 (2007).
5. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6(1): 11-22 (2005).
6. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91(18): 8324-8328 (1994).
7. Stancato LF, Silverstein AM, Owens-Grillo JK, Chow YH, Jove R, Pratt WB. The hsp90-binding antibiotic geldanamycin decreases raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of raf kinase. J Biol Chem 272(7): 4013-4020 (1997).
8. Schulte TW, Neckers LM. The benzoquinone ansamycin 17- allylamino-17-demethoxygeldanamycin binds to hsp90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42(4): 273-279 (1998)
9. Mollapour M, Neckers L. Post-translational modifications of hsp90 and their contributions to chaperone regulation. Biochimica et biophysica acta 1823(3): 648-655 (2012).
10. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8(4): 711-715 (1999).
11. Crowther RA, Goedert M. Abnormal tau-containing filaments in neurodegenerative diseases. J Struct Biol 130(2-3): 271-279 (2000).
12. Di Maria E, Tabaton M, Vigo T, Abbruzzese G, Bellone E, Donati C, et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol 47(3):74-377(2000).
13. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia ftdp-17. Nature 393(6686): 702-705 (1998).
14. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (p301l) tau protein. Nat Genet 25(4): 402-405 (2000).
15. Takeuchi H, Iba M, Inoue H, Higuchi M, Takao K, Tsukita K, et al. P301s mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PloS one 6(6): e21050 (2011).
16. Sahara N, Lewis J, DeTure M, McGowan E, Dickson DW, Hutton M, et al. Assembly of tau in transgenic animals expressing p301l tau: Alteration of phosphorylation and solubility. J Neurochem 83(6):1498-1508 (2002).
17. Koga H, Kaushik S, Cuervo AM. Protein homeostasis and aging: The importance of exquisite quality control. Ageing Res Rev 10(2): 205-215 (2011).
18. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, et al. Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci USA 100(2): 721-726 (2003).
19. Jinwal UK, O'Leary JC, 3rd, Borysov SI, Jones JR, Li Q, Koren J, et al. Hsc70 rapidly engages tau after microtubule destabilization. J Biol Chem 285(22): 16798-16805 (2010).
20. Elliott E, Tsvetkov P, Ginzburg I. Bag-1 associates with hsc70.Tau complex and regulates the proteasomal degradation of tau protein. J Biol Chem 282(51): 37276-37284 (2007).
21. Shimura H, Schwartz D, Gygi SP, Kosik KS. Chip-hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 279(6): 4869-4876 (2004).
22. Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, et al. Akt and chip coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci USA 105(9): 3622-3627 (2008).
23. Koren J, 3rd, Jinwal UK, Jin Y, O'Leary J, Jones JR, Johnson AG, et al. Facilitating akt clearance via manipulation of hsp70 activity and levels. J Biol Chem 285(4): 2498-2505 (2010).
24. Abisambra JF, Blair LJ, Hill SE, Jones JR, Kraft C, Rogers J, et al. Phosphorylation dynamics regulate hsp27-mediated rescue of neuronal plasticity deficits in tau transgenic mice. J Neurosci 30(46): 15374-15382 (2010).
25. Abisambra JF, Jinwal UK, Jones JR, Blair LJ, Koren J, 3rd, Dickey CA. Exploiting the diversity of the heat-shock protein family for primary and secondary tauopathy therapeutics. Curr Neuropharmacol 9(4): 623-631 (2011).
26. Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 17(6): 2225-2235 (2009).
27. Taldone T, Zatorska D, Patel PD, Zong H, Rodina A, Ahn JH, et al. Design, synthesis, and evaluation of small molecule hsp90 probes. Bioorg Med Chem 19(8): 2603-2614 (2011).
28. Janin YL. Atpase inhibitors of heat-shock protein 90, second season. Drug Discov Today 15(9-10): 342-353 (2010).
29. Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC. Heat shock protein 90: Inhibitors in clinical trials. J Med Chem 53(1): 3-17 (2010).
30. Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, et al. Hsp90 inhibitor pu-h71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 106(20): 8368-8373 (2009).
31. Sittler A, Lurz R, Lueder G, Priller J, Lehrach H, Hayer-Hartl MK, et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of huntington's disease. Hum Mol Genet 10(12): 1307-1315 (2001).
32. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a drosophila model for parkinson's disease. Science 295(5556): 865-868 (2002).
33. Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, Kamal A, et al. Hsp induction mediates selective clearance of tau phosphorylated at proline-directed ser/thr sites but not kxgs (mark) sites. FASEB J 20(6): 753-755 (2006).
34. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem 86(3): 582-590 (2013).
35. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102(19): 6990-6995 (2005).
36. Jinwal UK, Trotter JH, Abisambra JF, Koren J, 3rd, Lawson LY, Vestal GD, et al. The hsp90 kinase co-chaperone cdc37 regulates tau stability and phosphorylation dynamics. J Biol Chem 286(19): 16976-16983 (2011).
37. Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci USA 104(22): 9511-9516 (2007).
38. Jinwal UK, Miyata Y, Koren J, 3rd, Jones JR, Trotter JH, Chang L, et al. Chemical manipulation of hsp70 atpase activity regulates tau stability. J Neurosci: 29(39): 12079-12088 (2009).
39. Jones JR, Lebar MD, Jinwal UK, Abisambra JF, Koren J, 3rd, Blair L, et al. The diarylheptanoid (+)-ar,11s-myricanol and two flavones from bayberry (myrica cerifera) destabilize the microtubuleassociated protein tau. J Nat Prod 74(1): 38-44 (2011).
40. Jinwal UK, Koren J, O'Leary JC, Jones JR, Abisambra JF, Dickey CA. Hsp70 atpase modulators as therapeutics for alzheimer's and other neurodegenerative diseases. Mol Cell Pharmacol 2(2): 43-46 (2010).
41. George JM. The synucleins. Genome Biol 3(1): (2002).
42. Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, et al. Nigral and cortical lewy bodies and dystrophic nigral neurites in parkinson's disease and cortical lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol 57(4): 334-337 (1998).
43. Springer W, Kahle PJ. Mechanisms and models of alpha-synucleinrelated neurodegeneration. Curr Neurol Neurosci Rep 6(5): 432-436 (2006).
44. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 287(5456): 1265-1269 (2000).
45. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, et al. Human alpha-synuclein-harboring familial parkinson's disease-linked ala- 53 --> thr mutation causes neurodegenerative disease with alphasynuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99(13): 8968-8973 (2002).
46. Fernagut PO, Chesselet MF. Alpha-synuclein and transgenic mouse models. Neurobiol Dis 17(2): 123-130 (2004).
47. Uryu K, Richter-Landsberg C, Welch W, Sun E, Goldbaum O, Norris EH, et al. Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alphasynucleinopathies. Am J Pathol 168(3): 947-961 (2006).
48. Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ. The cochaperone carboxyl terminus of hsp70-interacting protein (chip) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem 280(25): 23727-23734 (2005).
49. Uversky VN. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 103(1): 17-37 (2007).
50. Wright JA, Wang X, Brown DR. Unique copper-induced oligomers mediate alpha-synuclein toxicity. FASEB J 23(8): 2384-2393 (2009).
51. Pountney DL, Voelcker NH, Gai WP. Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy. Hypothesis. Neurotox Res 7(1-2): 59-67 (2005).
52. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, et al. Alpha-synuclein, especially the parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322(5): 1089-1102 (2002).
53. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in lewy bodies. Nature 388(6645): 839-840 (1997).
54. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with parkinson's disease. Science 276(5321): 2045-2047 (1997).
55. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, et al. Both familial parkinson's disease mutations accelerate alphasynuclein aggregation. J Biol Chem 274(14): 9843-9846 (1999).
56. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30pro mutation in the gene encoding alpha-synuclein in parkinson's disease. Nat Genet 18(2): 106-108 (1998).
57. Giasson BI, Uryu K, Trojanowski JQ, Lee VM. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 274(12): 7619-7622 (1999).
58. El-Agnaf OM, Jakes R, Curran MD, Wallace A. Effects of the mutations ala30 to pro and ala53 to thr on the physical and morphological properties of alpha-synuclein protein implicated in parkinson's disease. FEBS letters 440(1-2): 67-70 (1998).
59. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, et al. Causal relation between alpha-synuclein gene duplication and familial parkinson's disease. Lancet 364(9440): 1169-1171 (2004).
60. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial parkinson's disease. Lancet 364(9440): 1167-1169 (2004).
61. Falsone SF, Kungl AJ, Rek A, Cappai R, Zangger K. The molecular chaperone hsp90 modulates intermediate steps of amyloid assembly of the parkinson-related protein alpha-synuclein. J Biol Chem 284(45): 31190-31199 (2009).
62. Luk KC, Mills IP, Trojanowski JQ, Lee VM. Interactions between hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly. Biochemistry 47(47): 12614-12625 (2008).
63. Tetzlaff JE, Putcha P, Outeiro TF, Ivanov A, Berezovska O, Hyman BT, et al. Chip targets toxic alpha-synuclein oligomers for degradation. J Biol Chem 283(26): 17962-17968 (2008).
64. Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M, et al. G2019s lrrk2 mutation in french and north african families with parkinson's disease. Ann Neurol 58(5): 784-787 (2005).
65. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of lrrk2-associated parkinson's disease: A case-control study. Lancet Neurol 7(7): 583-590 (2008).
66. Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M, et al. The g6055a (g2019s) mutation in lrrk2 is frequent in both early and late onset parkinson's disease and originates from a common ancestor. J Med Genet 42(11): e65 (2005).
67. Bras JM, Guerreiro RJ, Ribeiro MH, Januario C, Morgadinho A, Oliveira CR, et al. G2019s dardarin substitution is a common cause of parkinson's disease in a portuguese cohort. Mov Disord 20(12):1653-1655 (2005).
68. Ding X, Goldberg MS. Regulation of lrrk2 stability by the e3 ubiquitin ligase chip. PLoS One 4(6): e5949 (2009).
69. Lichtenberg M, Mansilla A, Zecchini VR, Fleming A, Rubinsztein DC. The parkinson's disease protein lrrk2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis 2: e196 (2011).
70. Ko HS, Bailey R, Smith WW, Liu Z, Shin JH, Lee YI, et al. Chip regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci USA 106(8): 2897-2902 (2009).
71. Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S, et al. Brain-permeable small-molecule inhibitors of hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synucleininduced toxicity. J Pharmacol Exp Ther 332(3): 849-857 (2010).
72. McLean PJ, Klucken J, Shin Y, Hyman BT. Geldanamycin induces hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun 321(3): 665-669 (2004).
73. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28(13): 3384-3391 (2008).
74. Shen HY, He JC, Wang Y, Huang QY, Chen JF, Geldanamycin induces heat shock protein 70 and protects against mptp-induced dopaminergic neurotoxicity in mice. J Biol Chem 280(48): 39962-39969 (2005).
75. Beilina A, Van Der Brug M, Ahmad R, Kesavapany S, Miller DW, Petsko GA, et al. Mutations in pten-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci USA 102(16): 5703-5708 (2005).
76. Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, Hamm-Clement J, et al. Transgenic mice expressing mutant a53t human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol cell Neurosci 24(2): 419-429 (2003).
77. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, et al. Hereditary early-onset parkinson's disease caused by mutations in pink1. Science 304(5674): 1158-1160 (2004).
78. Weihofen A, Ostaszewski B, Minami Y, Selkoe DJ. Pink1 parkinson mutations, the cdc37/hsp90 chaperones and parkin all influence the maturation or subcellular distribution of pink1. Hum Mol Genet 17(4): 602-616 (2008).
79. Moriwaki Y, Kim YJ, Ido Y, Misawa H, Kawashima K, Endo S, et al. L347p pink1 mutant that fails to bind to hsp90/cdc37 chaperones is rapidly degraded in a proteasome-dependent manner. Neurosci Res 61(1): 43-48 (2008).
80. Henn IH, Gostner JM, Lackner P, Tatzelt J, Winklhofer KF. Pathogenic mutations inactivate parkin by distinct mechanisms. J Neurochem 92(1): 114-122 (2005).
81. Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of parkinson's disease. J Mol Biol (2005) 351(5):1081-1100.
82. Huang C, Cheng H, Hao S, Zhou H, Zhang X, Gao J, et al. Heat shock protein 70 inhibits alpha-synuclein fibril formation via interactions with diverse intermediates. J Mol Biol 364(3): 323-336 (2006).
83. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: What do we really know? Nat Rev Neurol 7(11): 603-615 (2011).
84. Da Cruz S, Cleveland DW. Understanding the role of tdp-43 and fus/tls in als and beyond. Curr Opin Neurobiol 21(6): 904-919 (2011).
85. Mackenzie IR, Rademakers R, Neumann M. Tdp-43 and fus in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 9(10): 995-1007 (2010).
86. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in cu/zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362(6415): 59-62 (1993).
87. Joyce PI, Fratta P, Fisher EM, Acevedo-Arozena A. Sod1 and tdp- 43 animal models of amyotrophic lateral sclerosis: Recent advances in understanding disease toward the development of clinical treatments. Mamm Genome 22(7-8): 420-448 (2011).
88. Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, et al. Als-linked sod1 mutant g85r mediates damage to astrocytes and promotes rapidly progressive disease with sod1- containing inclusions. Neuron 18(2): 327-338 (1997).
89. Sehati S, Clement MH, Martins J, Xu L, Longo VD, Valentine JS, et al. Metabolic alterations in yeast lacking copper-zinc superoxide dismutase. Free Radic Biol Med 50(11): 1591-1598 (2011).
90. Strain J, Lorenz CR, Bode J, Garland S, Smolen GA, Ta DT, et al. Suppressors of superoxide dismutase (sod1) deficiency in saccharomyces cerevisiae. Identification of proteins predicted to mediate iron-sulfur cluster assembly. J Biol Chem 273(47): 31138-31144 (1998).
91. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited als determined by motor neurons and microglia. Science 312(5778): 1389-1392 (2006).
92. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11(3): 251-253 (2008).
93. Choi JS, Cho S, Park SG, Park BC, Lee DH. Co-chaperone chip associates with mutant cu/zn-superoxide dismutase proteins linked to familial amyotrophic lateral sclerosis and promotes their degradation by proteasomes. Biochem Biophy Res Commun 321(3): 574-583 (2004).
94. Urushitani M, Kurisu J, Tateno M, Hatakeyama S, Nakayama K, Kato S, et al. Chip promotes proteasomal degradation of familial als-linked mutant sod1 by ubiquitinating hsp/hsc70. J Neurochem 90(1): 231-244 (2004).
95. Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, Rothstein JD. Histological evidence of protein aggregation in mutant sod1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 8(6): 933-941 (2001).
96. Zetterstrom P, Graffmo KS, Andersen PM, Brannstrom T, Marklund SL. Proteins that bind to misfolded mutant superoxide dismutase- 1 in spinal cords from transgenic amyotrophic lateral sclerosis (als) model mice. J Biol Chem 286(23): 20130-20136 (2011).
97. Durham HD, Roy J, Dong L, Figlewicz DA. Aggregation of mutant cu/zn superoxide dismutase proteins in a culture model of als. J Neuropathol Exp Neurol 56(5): 523-530 (1997).
98. Roy J, Minotti S, Dong L, Figlewicz DA, Durham HD. Glutamate potentiates the toxicity of mutant cu/zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms. J Neurosci 18(23): 9673-9684 (1998).
99. Koyama S, Arawaka S, Chang-Hong R, Wada M, Kawanami T, Kurita K, et al. Alteration of familial als-linked mutant sod1 solubility with disease progression: Its modulation by the proteasome and hsp70. Biochem Biophys Res Commun 343(3): 719-730 (2006).
100. Batulan Z, Taylor DM, Aarons RJ, Minotti S, Doroudchi MM, Nalbantoglu J, et al. Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis. Neurobiol Dis 24(2): 213-225 (2006).
101. Liu J, Shinobu LA, Ward CM, Young D, Cleveland DW. Elevation of the hsp70 chaperone does not effect toxicity in mouse models of familial amyotrophic lateral sclerosis. J Neurochem 93(4): 875-882 (2005).
102. Kalmar B, Novoselov S, Gray A, Cheetham ME, Margulis B, Greensmith L. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the sod1 mouse model of als. J Neurochem 107(2): 339-350 (2008).
103. Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in als mice. Nat Med 10(4): 402-405 (2004).
104. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. Tdp-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351(3): 602-611 (2006).
105. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated tdp-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796): 130-133 (2006).
106. Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, et al. Tdp-43 a315t mutation in familial motor neuron disease. Ann Neurol 63(4): 535-538 (2008).
107. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. Tardbp mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40(5): 572-574 (2008).
108. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. Tdp-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319(5870): 1668-1672 (2008).
109. Kwiatkowski TJ, Jr., Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the fus/tls gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323(5918): 1205-1208 (2009).
110. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in fus, an rna processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323(5918): 1208-1211 (2009).
111. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mrna depletion and rna missplicing contribute to neuronal vulnerability from loss of tdp-43. Nat Neurosci 14(4): 459-468 (2011).
112. Sephton CF, Cenik C, Kucukural A, Dammer EB, Cenik B, Han Y, et al. Identification of neuronal rna targets of tdp-43-containing ribonucleoprotein complexes. J Biol Chem 286(2): 1204-1215 (2011).
113. Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, et al. Characterizing the rna targets and position-dependent splicing regulation by tdp-43. Nat Neurosci 14(4): 452-458 (2011).
114. Ling SC, Albuquerque CP, Han JS, Lagier-Tourenne C, Tokunaga S, Zhou H, Cleveland DW: Als-associated mutations in tdp-43 increase its stability and promote tdp-43 complexes with fus/tls. Proc Natl Acad Sci USA 107(30): 13318-13323 (2010).
115. Kryndushkin D, Wickner RB, Shewmaker F. Fus/tls forms cytoplasmic aggregates, inhibits cell growth and interacts with tdp-43 in a yeast model of amyotrophic lateral sclerosis. Protein Cell 2(3): 223-236 (2011).
116. Wang JW, Brent JR, Tomlinson A, Shneider NA, McCabe BD. The als-associated proteins fus and tdp-43 function together to affect drosophila locomotion and life span. J Clin Invest 121(10): 4118-4126 (2011).
117. Kim SH, Shanware NP, Bowler MJ, Tibbetts RS. Amyotrophic lateral sclerosis-associated proteins tdp-43 and fus/tls function in a common biochemical complex to co-regulate hdac6 mrna. J Biol Chem 285(44): 34097-34105 (2010).
118. Gregory JM, Barros TP, Meehan S, Dobson CM, Luheshi LM. The aggregation and neurotoxicity of tdp-43 and its als-associated 25 kda fragment are differentially affected by molecular chaperones in drosophila. PloS one 7(2): e31899 (2012).
119. Estes PS, Boehringer A, Zwick R, Tang JE, Grigsby B, Zarnescu DC. Wild-type and a315t mutant tdp-43 exert differential neurotoxicity in a drosophila model of als. Hum Mol Genet 20(12): 2308-2321 (2011).
120. Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. Efns guidelines on the clinical management of amyotrophic lateral sclerosis (mals)-revised report of an efns task force. Eur J Neurol 19(3): 360-375 (2012).
121. Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in sca1. Nat Genet 19(2): 148-154 (1998).
122. Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT, et al. Over-expression of inducible hsp70 chaperone suppresses neuropa thology and improves motor function in sca1 mice. Hum Mol Genet 10(14): 1511-1518 (2001).
123. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM. Suppression of polyglutamine-mediated neurodegeneration in drosophila by the molecular chaperone hsp70. Nat Genet 23(4): 425-428 (1999).
124. Al-Ramahi I, Lam YC, Chen HK, de Gouyon B, Zhang M, Perez AM, et al. Chip protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J Biol Chem 281(36): 26714-26724 (2006).
125. Choi JY, Ryu JH, Kim HS, Park SG, Bae KH, Kang S, et al. Cochaperone chip promotes aggregation of ataxin-1. Mol Cell Neurosci 34(1): 69-79 (2007).
126. Jana NR, Dikshit P, Goswami A, Kotliarova S, Murata S, Tanaka K, et al. Co-chaperone chip associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J Biol Chem 280(12): 11635-11640 (2005).
127. Williams AJ, Knutson TM, Colomer Gould VF, Paulson HL. In vivo suppression of polyglutamine neurotoxicity by c-terminus of hsp70-interacting protein (chip) supports an aggregation model of pathogenesis. Neurobiol Dis 33(3): 342-353 (2009).
128. Tsai HF, Lin SJ, Li C, Hsieh M. Decreased expression of hsp27 and hsp70 in transformed lymphoblastoid cells from patients with spinocerebellar ataxia type 7. Biochem Biophys Res Commun 334(4): 1279-1286 (2005).
129. Li L, Saegusa H, Tanabe T. Deficit of heat shock transcription factor 1-heat shock 70 kda protein 1a axis determines the cell death vulnerability in a model of spinocerebellar ataxia type 6. Genes Cells 14(11): 1253-1269 (2009).
130. Huen NY, Chan HY. Dynamic regulation of molecular chaperone gene expression in polyglutamine disease. Biochem Biophys Res Commun 334(4): 1074-1084 (2005).
131. Bailey CK, Andriola IF, Kampinga HH, Merry DE. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum Mol Genet 11(5): 515-523 (2002).
132. Kobayashi Y, Kume A, Li M, Doyu M, Hata M, Ohtsuka K, et al. Chaperones hsp70 and hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J Biol Chem 275(12): 8772-8778 (2000).
133. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, et al. 17-aag, an hsp90 inhibitor, ameliorates polyglutaminemediated motor neuron degeneration. Nat Med 11(10): 1088-1095 (2005).
134. Tokui K, Adachi H, Waza M, Katsuno M, Minamiyama M, Doi H, et al. 17-dmag ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an sbma model mouse. Hum Mol Genet 18(5): 898-910 (2009).
135. Thomas M, Harrell JM, Morishima Y, Peng HM, Pratt WB, Lieberman AP. Pharmacologic and genetic inhibition of hsp90- dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction. Hum Mol Genet 15(11): 1876-1883 (2006).
136. Adachi H, Katsuno M, Minamiyama M, Sang C, Pagoulatos G, Angelidis C, et al. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci 23(6): 2203-2211 (2003).
137. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU. Hsp70 and hsp40 chaperones can inhibit selfassembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci USA 97(14): 7841-7846 (2000).
138. Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, et al. Progressive decrease in chaperone protein levels in a mouse model of huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 13(13): 1389-1405 (2004).
139. Wang AM, Morishima Y, Clapp KM, Peng HM, Pratt WB, Gestwicki JE, et al. Inhibition of hsp70 by methylene blue affects signaling protein function and ubiquitination and modulates polyglutamine protein degradation. J Biol Chem 285(21): 15714-15723 (2004).
140. Baldo B, Weiss A, Parker CN, Bibel M, Paganetti P, Kaupmann K: A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (hsp90) client protein. J Biol Chem (2012) 287(2):1406-1414.
141. Adachi H, Waza M, Tokui K, Katsuno M, Minamiyama M, Tanaka F, et al. Chip overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J Neurosci: 27(19): 5115-5126 (2007).
142. Morishima Y, Wang AM, Yu Z, Pratt WB, Osawa Y, Lieberman AP. Chip deletion reveals functional redundancy of e3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins. Hum Mol Genet 17(24): 3942-3952 (2008).
143. Jana NR, Tanaka M, Wang G, Nukina N. Polyglutamine lengthdependent interaction of hsp40 and hsp70 family chaperones with truncated n-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity. Hum Mol Genet 9(13): 2009-2018 (2000).
144. Walter GM, Smith MC, Wisen S, Basrur V, Elenitoba-Johnson KS, Duennwald ML, et al. Ordered assembly of heat shock proteins, hsp26, hsp70, hsp90, and hsp104, on expanded polyglutamine fragments revealed by chemical probes. J Biol Chem 286(47): 40486-40493 (2011).
145. Jana NR, Nukina N: Bag-1 associates with the polyglutamineexpanded huntingtin aggregates. Neurosci Lett 378(3): 171-175 (2005).